Devapiran Jaishankar, MD
Medical Oncology · Greeneville, TNNPI 1225038490
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,714, more than ten times the $12 reported in 2019. That places this record below the midpoint for medical oncology clinicians in TN, where the typical reported total is $6,231.
Across 161 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$447
- Novartis$339
- AstraZeneca$289
- Merck$246
- Bristol Myers Squibb$212
- E.r. Squibb & Sons, L.L.C.$184
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,36693%
- Education$2507%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $447 |
| Novartis | 17 | $339 |
| AstraZeneca(2 entities) | 13 | $289 |
| Merck | 10 | $246 |
| Bristol Myers Squibb | 9 | $212 |
| E.r. Squibb & Sons, L.L.C. | 11 | $184 |
| Pfizer | 8 | $175 |
| Gilead | 8 | $161 |
| Genentech USA, Inc. | 7 | $133 |
| Ipsen Biopharmaceuticals, Inc | 4 | $131 |
| Regeneron Healthcare Solutions, Inc. | 4 | $120 |
| Sanofi | 5 | $116 |
| Daiichi Sankyo Inc. | 5 | $114 |
| AbbVie | 4 | $89 |
| Astellas Pharma US Inc | 4 | $84 |
| Bayer | 4 | $81 |
| Eisai Inc. | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Incyte Corporation | 2 | $53 |
| Beone Medicines USA, Inc. | 2 | $51 |
| Genmab U.S., Inc. | 2 | $48 |
| GSK | 2 | $41 |
| Sobi, Inc | 1 | $31 |
| Lilly USA, LLC | 2 | $31 |
| Array Biopharma Inc | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| EMD Serono, Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Iovance Biotherapeutics, Inc. | 1 | $21 |
| Exelixis Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Caris MPI, Inc. | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Seagen Inc. | 1 | $12 |
How this compares
$3,616 in reported general payments places this provider in the 35th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 30 | $457,984 |
| RevlimidLenalidomide | 22 | $365,775 |
| TukysaTucatinib | 11 | $245,604 |
| IbrancePalbociclib | 12 | $186,206 |
| Abiraterone Acetate | 17 | $27,981 |
| EliquisApixaban | 36 | $24,992 |
| Exemestane | 21 | $2,944 |
| Imatinib Mesylate | 13 | $2,709 |
| Letrozole | 107 | $2,434 |
| Prochlorperazine Maleate | 68 | $931 |
| Ondansetron Hcl | 74 | $813 |
| Hydrocortisone | 47 | $771 |
| Dexamethasone | 52 | $703 |
| Tamoxifen Citrate | 23 | $677 |
| Hydroxyurea | 34 | $632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $212 | $365,77522 claims |
| Seagen Inc.Tukysa | $12 | $245,60411 claims |
| PfizerIbrance, Eliquis | $175 | $211,19848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 101 medical oncology providers in Tennessee.
Other medical oncology in Greeneville
- William PaoNashville$838K
- Gregory VidalGermantown$360K
- Dana ThompsonNashville$339K
- Robert RamirezNashville$321K
- Mace RothenbergNashville$318K
- Melissa JohnsonNashville$290K
- Gina VaccaroCookeville$248K
- Jason ChandlerGermantown$234K
- Cathy EngNashville$231K
- David SpigelNashville$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.